Syngene is trading near key support of ₹645–₹669 ahead of its Q1FY26 results, with analyst Rohit Mehta flagging a potential breakout above ₹700. Despite weak YTD performance and high valuation, recent volume suggests bullish momentum. EPS dipped in Q4 FY25, but revenue and profit grew. Investors await results for signs of a trend reversal after a 29% drop from the all-time high.